ADAM10 and Alzheimer disease: The combination of ADAM10 and tau selected for this work was based on the novel hypothesis that during progression of AD, tau will be exposed to secretase-mediated cleavage either directly in the brain or as fragments generated by other brain proteases, which then become secondarily processed as they enter the circulation; however, this requires further studies.